Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 20 of 25, showing 10 Applications out of 241 total, starting on record 191, ending on 200

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

191.

ECCT/16/08/01   A5349/TBTC S31
    A5349/TBTC S31 “Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial”   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Walter Reed Project (Kericho county)
 
13-12-2016 View

192.

ECCT/17/09/02   WHO ACTION-I and ACTION-2 Trial
    A65913: A multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes       A65916: A multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the late preterm period in hospitals in low-resource countries to improve newborn outcomes   
Principal Investigator(s)
1. Frederick Were
2. John Kinuthia
3. Zahida Parveen Qureshi
4. Zahida Parveen Qureshi
5. Zahida Parveen Qureshi
Site(s) in Kenya
1. Coast Provincial General Hospital (Mombasa Level 5 Hospital) (Mombasa county)
2. Kiambu Level 4 Hospital (Kiambu county)
3. Thika Level 5 Hospital (Kiambu county)
4. Nakuru Level 5 Hospital (Nakuru county)
 
30-04-2018 View

193.

ECCT/14/10/02  
    Acronymn: CRASH-3   Short Title: Clinical Randomisation of an Antifibrinolytic in Significant Head Injury   Full Title: Tranexamic acid for the treatment of significant traumatic brain injury: an international randomised, double blind placebo controlled trial   ISRCTN15088122   ClinicalTrials.gov ID: NCT01402882    
Principal Investigator(s)
1. Kiboi Githinji Julius
2. Dullo Michael
3. Lallet Tasneem Essaji
Site(s) in Kenya
1. Kenyatta National Hospital (Nairobi City county)
2. Kitui District Hospital (Kitui county)
3. The Nairobi Hospital (Nairobi City county)
 
05-02-2015 View

194.

ECCT/21/06/01   ACTIV-2/A5401
    ACTIV-2/A5401 "Adaptive Platform Treatment Trial for Outpatients with COVID-19" (Adapt Out COVID)_   
Principal Investigator(s)
1. Charles Meja Kwobah
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Walter Reed Project (Kericho county)
 
01-11-2021 View

195.

ECCT/21/05/03   Adapt Out COVID
    Adaptive Platform Treatment trial for Outpatients with COVID-19   
Principal Investigator(s)
1. Kawango Agot
Site(s) in Kenya
1. Kenya Impact and Research Development Organization (K-IRDO) (Kisumu county)
2. KEMRI WALTER REED (Kericho county)
3. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county)
4. Kenya Medical Research Institute (Kisumu county)
 
28-07-2021 View

196.

ECCT/23/07/04   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Dr. Janet Oyieko
Site(s) in Kenya
1. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county)
2. Gertrude\'s Children Hospital (Nairobi City county)
3. KEMRI/CRDR Kemri Clinical Research Annex (Siaya county)
 
28-08-2023 View

197.

ECCT/23/08/02   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Nduba Videlis
Site(s) in Kenya
1. Getrudes Children Hospital (Nairobi City county)
2. KEMRI/CRDR (Siaya county)
3. Kombewa CRC (Kisumu county)
4. Kondele Childrens Hospital (Kisumu county)
 
18-10-2023 View

198.

ECCT/23/01/02   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Ogutu Bernhards Ragama
Site(s) in Kenya
1. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county)
2. Gertrude\'s Children Hospital (Nairobi City county)
3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds, (Siaya county)
4. Kombewa CRC (Kisumu county)
 
24-05-2023 View

199.

ECCT/23/01/03   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Githanga Githanga Nyokabi
Site(s) in Kenya
1. Gertrude\'s Children Hospital (Nairobi City county)
2. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county)
3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds (Siaya county)
4. Kombewa CRC (Kisumu county)
 
19-06-2023 View

200.

ECCT/14/09/01   Extension to study MALARIA-055 PRI (110021) for evaluation of long-term efficacy, safety and immunogenicity of GSK Biologicals’candidate malaria vaccine (SB257049) in infants and children in Africa
    An open extension to the phase III, multi-center study MALARIA-055 PRI (110021) to evaluate long-term efficacy, safety and immunogenicity of the RTS,S/AS01E candidate vaccine against malaria disease caused by Plasmodium falciparum in infants and children in Africa.   Study number: MALARIA-076 (200599)   
Principal Investigator(s)
1. Walter Otieno
Site(s) in Kenya
Kenya Medical Research Institute/Walter Reed Project
 
23-09-2015 View